Browsing Tag
GLP-1
41 posts
HIMS near 52-week low as FDA issues 30 GLP-1 warning letters
FDA sends 30 warning letters to GLP-1 compounders, targeting Hims & Hers Health (HIMS) as regulatory and legal pressure intensifies. Read what it means for investors and the sector.
Cipla and Orbicular bring first generic liraglutide for obesity to U.S. market, targeting $127m opportunity
Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read more.
Verdiva Bio advances VRB-101 into late-stage positioning with fully enrolled Phase 2b obesity study
Find out why Verdiva Bio’s Phase 2b enrollment milestone could determine whether once-weekly oral GLP-1 drugs can truly challenge injectables.
Why MetaVia’s patent move may matter more than early weight loss data in the obesity market
MetaVia Inc. secures patent protection for its dual incretin obesity drug DA-1726 through 2041. Find out why this matters for investors and competitors.
RD Nutrition Consultants acquired by Conscious Capital Growth and Petra Capital Partners in chronic care platform expansion
Private equity firms CCG and Petra Capital acquired RD Nutrition to scale chronic care and GLP-1 services. See what this signals for healthcare investors.
MetaVia (NASDAQ: MTVA) raises $9.3m to advance DA-1726 after positive Phase 1b obesity data
MetaVia raised $9.3M to fund DA-1726 after strong obesity trial results. Find out how this dual-agonist strategy could reshape the GLP-1 landscape.
Vanda Pharmaceuticals (NASDAQ: VNDA) wins long-awaited FDA approval for NEREUS, first new motion sickness drug in 40+ years
Find out how Vanda Pharmaceuticals’ FDA-approved NEREUS (tradipitant) is redefining motion sickness treatment after 40 years of stagnation. Read the full story now.
Mazdutide phase 1b results from Innovent Biologics offer new hope for adolescent obesity in China
Find out how Innovent Biologics’ mazdutide trial could change adolescent obesity treatment in China—phase 3 launch is next.
Can Novo Nordisk catch up—or will Lilly run away with the metabolic crown?
Explore how Eli Lilly and Company and Novo Nordisk are battling for dominance in the metabolic health market, and what could decide the next phase of the obesity drug race.
What’s next after Zepbound? Inside Eli Lilly and Company’s pipeline beyond GLP-1
Discover which drugs Eli Lilly and Company is betting on after Zepbound, including oral GLP-1 pills and next-generation incretins that could redefine the global obesity treatment market.